All In Biotech

Drug Trial Radar · NCT00200356

Edaravone-Sodium Ozagrel Comparative Post-Marketing Study on Acute Ischemic Stroke

Edaravone-Sodium Ozagrel (Thromboxane A2 Synthase Inhibitor) Comparative Post-Marketing Study on Acute Ischemic Stroke

Last checked: Nov 20, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 401 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

401

Actual

Start

Aug 31, 2004

Primary completion

Oct 31, 2006

Study completion Oct 31, 2006

Sponsor

Lead sponsor
ShionogiIndustry
Sponsor type
Industry
First posted
Sep 20, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 20 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is randomized, Sodium Ozagrel (Thromboxane A2 Synthase Inhibitor) controlled study on acute ischemic stroke. The primary endpoints were the rate of patients with modified Rankin Scale score of 0-1 at 3 months.

Conditions

  • Cerebral Infarction

Interventions

  • EdaravoneDrug

    Edaravone, at 30 mg, is intravenously administered by drip over 30 minutes b.i.d., in the morning and the evening.

  • Sodium OzagrelDrug

    Sodium Ozagrel, at 80 mg, is intravenously administered by drip over 2 hours b.i.d., in the morning and the evening.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. the Rate of Patients With a Modified Rankin Scale Score of 0-1Time frame: 3 months

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.